Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression

Prostaglandins and Other Lipid Mediators

Volumn 83, Issue 4, 2007, Pages 320-328

  Bianchini, Francesca ^a   Massi, Daniela ^a   Marconi, Chiara ^a   Franchi, Alessandro ^a   Baroni, Gianna ^a   Santucci, Marco ^a   Mannini, Antonella ^a   Mugnai, Gabriele ^a   Calorini, Lido ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cyclo oxygenase 2 (COX 2); F10 M3 murine melanoma cells; Human melanomas; Immunoistochemical analysis; Thioglycollate elicited murine macrophages; Tumor associated macrophages (TAMs)

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2; THIOGLYCOLIC ACID;

ADULT; AGED; ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER STAGING; CARCINOMA IN SITU; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG RESEARCH; DYSPLASTIC NEVUS; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MELANOCYTIC NEVUS; MELANOMA; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CYCLOOXYGENASE 2; DISEASE PROGRESSION; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES, PERITONEAL; MALE; MELANOMA; MICE; MICE, INBRED C57BL; MIDDLE AGED; NEVUS; SKIN NEOPLASMS; THIOGLYCOLATES; TUMOR CELLS, CULTURED;

EID: 34248171189     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2007.03.003     Document Type: Article

References (37)

1. Fidler I.J., and Schroit A.J. Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim Biophys Acta 948 (1988) 151-173
2. Whitworth P.W., Pak C.C., Esgro J., et al. Macrophages and cancer. Cancer Metastasis Rev 8 (1990) 319-351
3. Elgert K.D., Alleva D.G., and Mullins D.W. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64 (1998) 275-290
4. Hsu M.Y., Meier F., and Herlyn M. Melanoma development and progression: a conspiracy between tumor and host. Differentiation 70 (2002) 522-536
5. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4 (2004) 71-78
6. Sica A., Schioppa T., Mantovani A., and Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42 (2006) 717-727
7. Crowther M., Brown N.J., Bishop E.T., and Lewis C.E. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol 70 (2001) 478-490
8. Stout R.D., Jiang C., Matta B., et al. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 175 (2005) 342-349
9. Lewisn C.E., and Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res 66 (2006) 605-612
10. Fidler I.J. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat Rev 3 (2003) 1-6
11. Funk C.D. Prostaglandin and leukotrienes: advances in eicosanoid biology. Science 294 (2001) 1871-1874
12. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 30 (2000) 3-21
13. Tucker O.N., Dannenberg O.J., Yang E.K., et al. Cyclooxygenase-2 expression is upregulated in human pancreatic cancer. Cancer Res 59 (1999) 987-990
14. Wolff H., Saukkonen K., Anttila S., et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58 (1998) 4997-5001
15. Chan G., Boyle J.O., Yang E.K., et al. Cyclooxygenase-2 expression is upregulated in squamous cell carcinoma of the head and neck. Cancer Res 59 (1999) 991-994
16. Denkert C., Weichert W., Pest E., et al. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res 64 (2004) 189-195
17. Thun M.J., Namboodiri M.M., and Heath Jr. C.W. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325 (1991) 1593-1596
18. Schreinemachers D.M., and Everson R.B. Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 5 (1994) 138-146
19. Taketo M.M. Cyclooxygenase inhibitors in tumorigenesis (Part I). J Natl Cancer Inst 90 (1998) 1529-1536
20. Taketo M.M. Cyclooxygenase inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 90 (1998) 1609-1615
21. Oshima M., Dinchuk J.E., Kargman S.L., et al. Suppression of intestinal polyposis in APCΔ716 knockout mice by inhibition of prostaglandin endoperoxide synthase-2 (COX-2). Cell 87 (1996) 803-809
22. Denkert C., Kobel M., Berger S., et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 61 (2001) 303-308
23. Gattoni-Celli S., Calorini L., Simile M.M., and Ferrone S. Modulation by MHC class I antigens of the biology of melanoma cells. Non-immunological mechanisms. Melanoma Res 3 (1993) 285-289
24. Cecconi O., Calorini L., Mannini A., et al. Enhancement of lung-colonizing potential of murine tumor cell lines co-cultivated with activated macrophages. Clin Exp Metastasis 15 (1997) 94-101
25. Gordon S. Alternative activation of macrophages. Nat Rev 3 (2003) 23-35
26. Orlic D., Anderson S., Biesecker L.G., et al. Pluripotent hematopoietic stem cells contain high levels of mRNA for c-kit, GATA-2, p45 NF-E2, and c-myb and low levels or no mRNA for c-fms and the receptors for granulocyte colony-stimulating factor and interleukins 5 and 7. Proc Natl Acad Sci U S A 92 (1995) 4601-4605
27. Pouliot M., Clish C.B., Petasis N.A., et al. Lipoxin A(4) analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: a role for cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry 25 (2000) 4761-4768
28. Bamba H., Ota S., Kato A., et al. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int J Cancer 83 (1999) 470-475
29. Condeelis J., and Segall J.E. Intravital imaging of cell muvement. Nat Rev Cancer 3 (2003) 921-930
30. Blanke CD, Masferrer JL. Chemotherapy with Cyclooxygenase-2 inhibitors in the treatment of malignant disease: pre-clinical rationale and preliminary results of clinical trials. In: Dannenberg AJ, DuBois RN (editors) Prog Exp Tum Res, Kurger, Basel, 2003. vol. 37, pp. 243-260.
31. Eberhart C.E., Coffey R.J., Radhika A., et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
32. Abou-Issa H.M., Alshafie G.A., Seibert K., et al. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res 21 (2001) 3425-3432
33. Bertagnolli M.M., Eagle C.J., Zauber A.G., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355 (2006) 873-884
34. Arber N., Eagle C.J., Spick J., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355 (2006) 885-895
35. Baron J.A., Sandler R.S., Bresalier R.S., et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131 (2006) 1674-1682
36. Calder P.C. Polyunsaturated fatty acids, inflammation, and immunity. Lipids 36 (2001) 1007-1024
37. Young M.R.Y. Eicosanoids and the immunology of cancer. Cancer Metastasis Rev 13 (1994) 337-348